Opthea is developing novel biologic inhibitors of angiogenesis (blood vessel growth), lymphangiogenesis (lymphatic vessel growth) and vascular leakage for the treatment of ophthalmic diseases.
Opthea's lead compound, OPT-302, is a soluble receptor that specifically and potently blocks the activity of two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, that are involved in the progression of both retinal and corneal diseases.
Opthea is currently developing OPT-302 for the treatment of wet age-related macular degeneration (wet AMD).
Opthea Pty Ltd is a private, 100% owned subsidiary of Circadian Technologies Limited based in Melbourne, Australia. Enquiries can be directed to: email@example.com